/ Protocols / Wolverine
WOLVERINE
BPC-157 + TB-500 · the regenerative stack
BPC-157 is the local medic. TB-500 is the dispatcher. Run together, they compress the healing window from months to weeks. The most-run stack in this registry.
// 01
What it is
Two peptides. Two mechanisms. One outcome: the body stops breaking and starts fixing.
BPC-157 — Body Protection Compound — is a 15-amino-acid fragment of a protein your stomach produces to keep itself from dissolving. Researchers pulled out the sequence that does the protecting. It acts locally: angiogenesis at the wound site, growth-hormone receptor upregulation on tendon cells, cytokine suppression, collagen synthesis.
TB-500 is a synthetic 7-amino-acid fragment corresponding to the active region (residues 17–23, acetylated) of native Thymosin Beta-4. TB-500 is not TB-4. TB-500 is the piece that does the regenerative work, isolated and shelf-stable. It acts systemically: mobilises progenitor cells from reservoir tissue to damaged tissue, upregulates actin, and reduces inflammation across muscle, tendon, cardiac and neural systems.
// 02
Mechanism
BPC-157 · LOCAL
- — Angiogenesis at the wound site
- — GH receptor upregulation on tendon fibroblasts
- — Nitric oxide pathway modulation
- — Cytokine suppression — breaks the inflammation loop
- — Collagen synthesis
- — Gastric-stable → oral liposomal viable for gut pathology
TB-500 · SYSTEMIC
- — Actin upregulation (cell scaffolding)
- — Stem / progenitor cell mobilisation to injury
- — Angiogenesis — stacks with BPC-157
- — Anti-inflammatory across multiple tissue types
- — Keeps repair cells alive long enough to finish the job
// 03
Dosing
The math people actually need at the kitchen counter. Units on a U-100 insulin syringe, not lit-review microgram ranges.
Combo vial
10+10
mg BPC / mg TB-500
Diluent
3.0
mL bac water
Conc. total
6.67
mg/mL (3.33 each)
Starting dose
10–20u
M–F · U-100 units
≈ 333–667 mcg of each peptide per injection · SubQ near the site when anatomically reasonable · start at 10 units, move to 20 if the response is slow.
// Reconstitution · watch
Mixing the vial the first time is the moment most people get it wrong. Watch once before you draw.
- › Swirl, don’t shake. Proteins fracture under shear.
- › Reconstitute once — store the mixed vial refrigerated, use within 30 days.
- › SubQ rotation: abdomen, flank, outer thigh. Alcohol prep. Sharps bin.
// 04
Routes
SUBCUTANEOUS
Default. Highest bioavailability. Orthopaedic and systemic dosing. Inject near the injury when anatomically reasonable.
ORAL LIPOSOMAL
BPC-157 only. Gastric-stable. Preferred for GI pathology: ulcers, leaky gut, IBS, post-surgical gut.
TOPICAL
Limited evidence. Not primary. Adjunctive for surface wounds or local skin healing alongside SubQ.
// 05
Cycle + timeline
WEEKS 1–2
Inflammation drops. Sleep often improves. Pain starts to disengage.
WEEKS 3–6
Tissue remodelling. The injury stops dominating your day.
WEEKS 8–12
Structural repair. What was a problem usually isn't anymore.
Individual response varies. So does injury severity. So does the honesty of the person answering “how bad is it, really.”
// 06
Contraindications
- ⚠Active malignancy. Angiogenic peptides are a hard stop until oncology clears.
- ⚠Pregnancy / lactation. No data. Don't.
- ⚠Active bleeding or pre-op. Stop 2 weeks before elective surgery.
- ⚠Known copper sensitivity (GHK-Cu).
- ⚠If you have questions, talk to a licensed physician before starting.
// 07
Stacks with
// 08
Community data
Self-reported outcomes from 412 registered participants. Polls are anonymous and contribute to IRB PPRN-001-2025. Self-selected sample — read it as signal, not as a controlled trial.
SATISFACTION
- Very satisfied68%
- Somewhat satisfied22%
- Neutral6%
- Dissatisfied4%
n = 412
WHEN DID YOU SEE RESULTS?
- Weeks 1–231%
- Weeks 3–649%
- Weeks 7–1215%
- No change / TBD5%
n = 378
SIDE EFFECT SEVERITY
- None72%
- Mild (flush, fatigue)21%
- Moderate (GI, headache)7%
- Severe0%
n = 412
// Disclaimer
Nothing on killer.health is medical advice. This platform is a research registry and information aggregator. Content is drawn from peer-reviewed publications, clinical protocols and community sources. killer.health does not endorse any compound, supplier or treatment. Always work with a licensed physician inside an established clinical relationship before starting, stopping or modifying any protocol. Data capture is governed by IRB PPRN-001-2025. Anonymous submissions are the default.